-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
January 15, 2022/eMedClub News/--Recently, ABL Bio, a Korean biotechnology company focusing on the development of new antibody drugs for tumor immunity and neurodegenerative diseases, announced that it has partnered with French pharmaceutical giant Sanofi.
Entered into an exclusive worldwide collaboration and license agreement to co-develop and commercialize ABL301
.
Using ABL Bio's proprietary Grabody-B platform technology, ABL301 can effectively cross the blood-brain barrier (BBB) and is a potential "first-in-class" bispecific antibody in preclinical stage targeting α-synapses Nuclear protein (α-syn) and insulin-like growth factor 1 receptor (IGF1R) for the treatment of Parkinson's disease (PD) and other potential indications
.
PD is the most common neurodegenerative movement disorder, affecting more than 10 million people worldwide
.
It is caused by damage to nerve cells (neurons) in the brain, resulting in lower levels of dopamine (a neurotransmitter involved in processes such as memory or movement) in patients, and the primary and most debilitating symptom is the progression of motor control loss of sex
.
Often the early symptoms of this disorder are tremors in one hand
.
Other symptoms include stiffness, spasticity, and dyskinesia (involuntary, unsteady, writhing movements of the face, arms, legs, or trunk)
.
Dopamine substitutes, such as levodopa, are currently commonly used to reduce symptoms of the disease, but their effects diminish as the disease progresses
.
With the development of medical technology, scientists have discovered a variety of potential treatment options to solve PD, such as gene therapy, antibody drugs, and the widely-promising stem cell therapy
.
However, due to the existence of the blood-brain barrier, it is difficult for therapeutic drugs to work, which has become one of the main obstacles to drug development in the central nervous system (CNS)
.
The molecular shuttles generated by the Grabody-B platform developed by ABL Bio facilitate the CNS penetration of therapeutic drugs by directly generating bispecific antibodies, or antibody-drug conjugates (ADCs)
.
Grabody-B is a non-neutralizing anti-IGF1R antibody and therefore does not interfere with IGF1R signaling
.
In preclinical studies, compared with monoclonal antibodies, Grabody-B significantly improved the blood-brain barrier permeability of various therapeutic antibodies in rodents and non-human primates, with better efficacy or drug Efficacy
.
IGF1R has relatively specific expression and non-neutralizing properties in the CNS, so Grabody-B is considered to be a safe and effective shuttle that can enhance the therapeutic efficacy of various CNS-related diseases in the clinic
.
▲Image source: ABL Bio's official website ABL301 is a bispecific antibody, consisting of an anti-α-syn antibody and Grabody-B, for the treatment of synucleinopathies including Parkinson's disease
.
In preclinical studies, the anti-α-syn domain of ABL301 showed robust recognition and high affinity for pathological aggregates with minimal affinity for monomeric α-syn
.
▲Image source: ABL Bio's official website In the Parkinson's disease mouse model, ABL301 showed better reduction of brain α-syn than α-syn monoclonal antibody due to its superior blood-brain barrier penetration ability.
The effect of deposition
.
ABL301 has two mechanisms of action (MoA) on α-syn: ①promoting the phagocytosis of extracellular α-syn by microglia; ②inhibiting the intercellular transport of α-syn
.
▲ Image source: ABL Bio’s official website According to the terms of the agreement, ABL Bio will receive an upfront payment of $75 million and is eligible to receive up to $985 million in future development, regulatory and commercial milestone payments and net product sales of royalties
.
Sanofi will receive exclusive worldwide development and commercialization rights to ABL301
.
Concurrently, ABL Bio will lead the preclinical development and Phase 1 clinical trials of ABL301
.
Thereafter, Sanofi will be responsible for further clinical development, regulatory approval and commercialization of ABL301 worldwide
.
Dr.
Sang Hoon Lee, CEO of ABL Bio, said: "The breakthrough collaboration with Sanofi demonstrates the great potential of our innovative bispecific antibody technology
.
We will continue to develop the Grabody-B platform and expand its use in other neurodegenerative diseases .
Applicability in sexually transmitted diseases (such as Alzheimer's disease), and contribute to improving the lives of patients around the world
.
" ABL Bio is one of the representatives of Korean antibody engineering technology and one of the leading biotechnology companies in Korea.
the company line comprises a plurality of double-antibody RESEARCH, ADC, through the blood-brain barrier of the double-antibody and the like
.
ABL Bio's most important layout is bispecific antibodies, and it has many direct or indirect partnerships with Chinese companies
.
The Chinese rights and interests of VEGF/DLL4 double antibody are held by Kewang Bio (introduced by TRIGR), and the Claudin18.
2/4-1BB double antibody and PD-L1/4-1BB double antibody are jointly developed with Tianjing Bio, and the ROR1 ADC in China The interest is held by CStone (introduced by LCB)
.
▲Image source: ABL Bio official website Reference: 1.
https:// -abl301-for-the-treatment-of-parkinson-s-disease/
Entered into an exclusive worldwide collaboration and license agreement to co-develop and commercialize ABL301
.
Using ABL Bio's proprietary Grabody-B platform technology, ABL301 can effectively cross the blood-brain barrier (BBB) and is a potential "first-in-class" bispecific antibody in preclinical stage targeting α-synapses Nuclear protein (α-syn) and insulin-like growth factor 1 receptor (IGF1R) for the treatment of Parkinson's disease (PD) and other potential indications
.
PD is the most common neurodegenerative movement disorder, affecting more than 10 million people worldwide
.
It is caused by damage to nerve cells (neurons) in the brain, resulting in lower levels of dopamine (a neurotransmitter involved in processes such as memory or movement) in patients, and the primary and most debilitating symptom is the progression of motor control loss of sex
.
Often the early symptoms of this disorder are tremors in one hand
.
Other symptoms include stiffness, spasticity, and dyskinesia (involuntary, unsteady, writhing movements of the face, arms, legs, or trunk)
.
Dopamine substitutes, such as levodopa, are currently commonly used to reduce symptoms of the disease, but their effects diminish as the disease progresses
.
With the development of medical technology, scientists have discovered a variety of potential treatment options to solve PD, such as gene therapy, antibody drugs, and the widely-promising stem cell therapy
.
However, due to the existence of the blood-brain barrier, it is difficult for therapeutic drugs to work, which has become one of the main obstacles to drug development in the central nervous system (CNS)
.
The molecular shuttles generated by the Grabody-B platform developed by ABL Bio facilitate the CNS penetration of therapeutic drugs by directly generating bispecific antibodies, or antibody-drug conjugates (ADCs)
.
Grabody-B is a non-neutralizing anti-IGF1R antibody and therefore does not interfere with IGF1R signaling
.
In preclinical studies, compared with monoclonal antibodies, Grabody-B significantly improved the blood-brain barrier permeability of various therapeutic antibodies in rodents and non-human primates, with better efficacy or drug Efficacy
.
IGF1R has relatively specific expression and non-neutralizing properties in the CNS, so Grabody-B is considered to be a safe and effective shuttle that can enhance the therapeutic efficacy of various CNS-related diseases in the clinic
.
▲Image source: ABL Bio's official website ABL301 is a bispecific antibody, consisting of an anti-α-syn antibody and Grabody-B, for the treatment of synucleinopathies including Parkinson's disease
.
In preclinical studies, the anti-α-syn domain of ABL301 showed robust recognition and high affinity for pathological aggregates with minimal affinity for monomeric α-syn
.
▲Image source: ABL Bio's official website In the Parkinson's disease mouse model, ABL301 showed better reduction of brain α-syn than α-syn monoclonal antibody due to its superior blood-brain barrier penetration ability.
The effect of deposition
.
ABL301 has two mechanisms of action (MoA) on α-syn: ①promoting the phagocytosis of extracellular α-syn by microglia; ②inhibiting the intercellular transport of α-syn
.
▲ Image source: ABL Bio’s official website According to the terms of the agreement, ABL Bio will receive an upfront payment of $75 million and is eligible to receive up to $985 million in future development, regulatory and commercial milestone payments and net product sales of royalties
.
Sanofi will receive exclusive worldwide development and commercialization rights to ABL301
.
Concurrently, ABL Bio will lead the preclinical development and Phase 1 clinical trials of ABL301
.
Thereafter, Sanofi will be responsible for further clinical development, regulatory approval and commercialization of ABL301 worldwide
.
Dr.
Sang Hoon Lee, CEO of ABL Bio, said: "The breakthrough collaboration with Sanofi demonstrates the great potential of our innovative bispecific antibody technology
.
We will continue to develop the Grabody-B platform and expand its use in other neurodegenerative diseases .
Applicability in sexually transmitted diseases (such as Alzheimer's disease), and contribute to improving the lives of patients around the world
.
" ABL Bio is one of the representatives of Korean antibody engineering technology and one of the leading biotechnology companies in Korea.
the company line comprises a plurality of double-antibody RESEARCH, ADC, through the blood-brain barrier of the double-antibody and the like
.
ABL Bio's most important layout is bispecific antibodies, and it has many direct or indirect partnerships with Chinese companies
.
The Chinese rights and interests of VEGF/DLL4 double antibody are held by Kewang Bio (introduced by TRIGR), and the Claudin18.
2/4-1BB double antibody and PD-L1/4-1BB double antibody are jointly developed with Tianjing Bio, and the ROR1 ADC in China The interest is held by CStone (introduced by LCB)
.
▲Image source: ABL Bio official website Reference: 1.
https:// -abl301-for-the-treatment-of-parkinson-s-disease/
